Key facts
- It has raised $500K; the latest was Seed Round in Mar 2026.
- Notable investors include Breakthrough Victoria, BioCurate, Brandon Biocatalyst, Monash University, Uniseed.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for xCystence Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for xCystence Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About xCystence Bio
Developer of polycystic kidney disease therapeutics designed to prevent the formation of new cysts and the growth of existing ones. The company's technology identifies and blocks a specific cell signaling pathway active in genetic kidney disease to prevent and slow down the progression, enabling the healthcare sector to slow disease progression and improve patient quality of life.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2023
- Ownership
- Privately Held (backing)
xCystence Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in xCystence Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on xCystence Bio in its N-PORT filings yet. We sweep new filings monthly.